公开(公告)号：US20190135931A1

公开(公告)日：2019-05-09

申请号：US16183988

申请日：2018-11-08

Applicant: Novartis AG

Inventor： Christoph Heusser ,  Julia Neugebauer ,  Eveline Schaadt ,  Stefanie Urlinger ,  Maximilian Woisetschlaeger

IPC: C07K16/28

Abstract: The present invention relates to antibodies that specifically bind to the BAFF receptor (BAFFR). The invention more specifically relates to specific antibodies that are BAFFR antagonists with in vivo B cell depleting activity and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by killing or depleting B cells, such as systemic lupus erythematosus or rheumatoid arthritis or other autoimmune diseases or lymphomas, leukemias and myelomas.

公开(公告)号：US12054555B2

公开(公告)日：2024-08-06

申请号：US17127755

申请日：2020-12-18

Applicant: NOVARTIS AG

Inventor： Marta Cosenza ,  Christoph Heusser ,  Julia Neugebauer ,  Eveline Schaadt ,  Stefanie Urlinger ,  Maximilian Woisetschlaeger

IPC: C07K16/28 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K9/20 ,  A61K39/395 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  C07K14/705 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/19 ,  A61K9/2018 ,  A61K39/39591 ,  A61K47/10 ,  A61K47/183 ,  A61K47/26 ,  C07K14/70578 ,  C07K16/2896 ,  A61K39/39533 ,  A61K39/3955 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73

Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

公开(公告)号：US10899841B2

公开(公告)日：2021-01-26

申请号：US16294374

申请日：2019-03-06

Applicant: Novartis AG

Inventor： Marta Cosenza ,  Christoph Heusser ,  Julia Neugebauer ,  Eveline Schaadt ,  Stefanie Urlinger ,  Maximilian Woisetschlaeger

IPC: A61K39/395 ,  C07K14/705 ,  C07K14/71 ,  C07K16/28 ,  A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K47/18 ,  A61K47/26 ,  A61K47/10 ,  A61K39/00

Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

公开(公告)号：US20190194341A1

公开(公告)日：2019-06-27

申请号：US16294374

申请日：2019-03-06

Applicant: Novartis AG

Inventor： Marta COSENZA ,  Christoph Heusser ,  Julia Neugebauer ,  Eveline Schaadt ,  Stefanie Urlinger ,  Maximillan Woisetschlaeger

IPC: C07K16/28 ,  A61K47/10 ,  A61K9/08 ,  A61K9/19 ,  A61K39/395 ,  A61K47/18 ,  A61K47/26 ,  A61K9/00

CPC classification number: C07K16/2878 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/19 ,  A61K39/39533 ,  A61K39/3955 ,  A61K39/39591 ,  A61K47/10 ,  A61K47/183 ,  A61K47/26 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73

Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

公开(公告)号：US20180179290A1

公开(公告)日：2018-06-28

申请号：US15895055

申请日：2018-02-13

Applicant: Novartis AG

Inventor： Marta Cosenza ,  Christoph Heusser ,  Julia Neugebauer ,  Eveline Schaadt ,  Stefanie Urlinger ,  Maximilian Woisetschlaeger

IPC: C07K16/28 ,  A61K47/18 ,  A61K9/08 ,  A61K9/19 ,  A61K39/395 ,  A61K47/10 ,  A61K9/00 ,  A61K47/26 ,  A61K39/00

CPC classification number: C07K16/2878 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/19 ,  A61K39/39533 ,  A61K39/3955 ,  A61K39/39591 ,  A61K47/10 ,  A61K47/183 ,  A61K47/26 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73

Abstract: Anti-BAFFR antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant and/or a free amino acid.

公开(公告)号：US09988455B2

公开(公告)日：2018-06-05

申请号：US15390067

申请日：2016-12-23

Applicant: NOVARTIS AG

Inventor： Kurt Alex Heldwein ,  Jennifer Brogdon ,  William Dole ,  John Trauger ,  Yuting Tang ,  Julia Neugebauer ,  Annika Schmid

IPC: A61P9/08 ,  A61P9/04 ,  A61P9/10 ,  A61P9/12 ,  A61K39/395 ,  C07K16/28 ,  C07K14/47

CPC classification number: C07K16/2851 ,  A61K39/3955 ,  A61K2039/505 ,  A61P9/04 ,  A61P9/08 ,  A61P9/10 ,  A61P9/12 ,  C07K14/33 ,  C07K14/4726 ,  C07K16/28 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same.